加巴喷丁与卡马西平治疗糖尿病痛性神经病变的临床疗效对比观察被引量：2

Comparison of clinical efficacy of Gaba Martin and C Masi Bing in the treatment of diabetic neuropathic pain

下载PDF

导出

摘要目的:对加巴喷丁与卡马西平治疗糖尿病痛性神经病变的临床疗效与不良反应进行对比观察。方法:将广州市番禺区中医院2015年6月~2017年1月收治的70例2型糖尿病痛性神经病变患者随机分成两组,加巴喷丁治疗组与卡马西平对照组。治疗时间为4周。疼痛程度测定使用视觉模拟评分法VAS评定。结果:治疗2周、4周后,两组患者疼痛程度均较治疗前明显改善,但加巴喷丁治疗组较卡马西平对照组疼痛缓解更显著,差异有统计学意义(P<0.01),不良反应发生率更低,差异有统计学意义(P<0.05)。结论:在糖尿病痛性神经病变的治疗中,加巴喷丁比卡马西平疗效更显著,不良反应更少,是治疗糖尿病痛性神经病变更理想的药物。 Objective To compare the clinical efficacy and side effects of gabapentin and C Masi Bing in the treatment of diabetic neuropathic pain.Method The Panyu District TCM Hospital of Guangzhou city from June2015to January2017treated70cases of patients with type2diabetic painful neuropathy,they were randomly divided into two groups,gabapentin treatment group,C Masi Bing group,the treatment time was4weeks,the degree of pain was measured using a visual analogue scale assessment VAS.Results After2weeks and4weeks treatment,two groups of patients with pain were significantly improved after treatment,but the treatment group than the control group Gaba Martin C Masi Bing pain relief was more significant(P<0.01),the incidence of adverse reaction was lower(P<0.05).Conclusion Gabapentin is more effective and effective than carbamazepine in the treatment of diabetic painful neuropathy.It is an ideal drug for the treatment of diabetic neuropathic pain.

作者龙可朱凯云闵珊张敬华 LONG Ke;ZHU Kai-yun;MIN Shan(Panyu District Hospital of traditional Chinese medicine,Guangzhou 511400,China;Guangzhou women and children medical center,Guangzhou 510623,China)

机构地区广州市番禺区中医院广州市妇女儿童医疗中心

出处《吉林医学》 CAS 2018年第3期477-478,共2页 Jilin Medical Journal

关键词糖尿病痛性神经病变加巴喷丁卡马西平 Diabetic neuropathic pain Gabapentin C Masi Bing

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献2

1陈文斌,汤义平,赵群峰,张丽霞.度洛西汀治疗糖尿病性神经痛56例临床疗效观察[J].浙江实用医学,2013,18(3):165-166. 被引量：4
2朱志刚,郭向阳.加巴喷丁治疗糖尿病痛性神经病变的疗效观察[J].中国实用神经疾病杂志,2014,17(16):41-42. 被引量：10

二级参考文献19

1Snow S, Kirwan J R. Visual analogue scales: a source of error. AnnRheum Dis, 1988,47(6) : 526.
2Van Acker K,Bouhassira D,De Bacquer D, et al.Prevalence and im-pact on quality of life of peripheral neuropathy with or without neuro-pathic pain in type 1 and type 2 diabetic patients attending hospitaloutpatients clinics. Diabetes Metab,2009,35 (3): 206.
3Ziegler D, Pritchett Y L, Wang F, et al. Impact of disease characteris-tics on the efficacy of duloxetine in diabetic peripheral neuropathicpain. Diabetes Care,2007,30(3) :664.
4Wernicke J F,Pritchett Y L, Souza D N,et al. Arandomized controlledtrial of duloxetine in diabetic peripheral neuropathic pain. Neurology,2006,67(8):1411.
5Coldstein D J, Lu Y, Detke M J, et al. Duloxetine vs placebo in pa-tients with painful diabetic neuropathy. Pain, 2005,116(1 - 2) : 109.
6Renk,Dubner R. Descending modulation in persistent pain: an update.Pain, 2002,100(1-2):1.
7Perahia D G, Pritchett Y L, Desaiah D,et al. Efficacy of duloxetine inpainful symptoms: an analgesic or antidepressant effect. Int Clin Psy-chopharmacol, 2006,21(6):311.
8Raskin J, Pritchett Y L, Wang F, et al. A double - blind, randomizedmulticenter trial comparing duloxetine with placebo in the managementof diabetic peripheral neuropathic pain.Pain Med,2005,6(5) :346.
9Tremont-Lukats IW, Meg C, BackonjaMM. Anticonvulsants :or neuropathic pain syndromes: mechanisms of action andplace in therapy[J]. Drugs,2000,60(5)1 029- 1 052.
10Snow S,Kirwan J R. Visual analogue scales:a source of error [J]. Ann Rheum Dis,1988,47(6) :526-527.